158 related articles for article (PubMed ID: 27517148)
1. KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review.
Kim BJ; Jang HJ; Kim JH; Kim HS; Lee J
Oncotarget; 2016 Sep; 7(36):58001-58006. PubMed ID: 27517148
[TBL] [Abstract][Full Text] [Related]
2. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
[TBL] [Abstract][Full Text] [Related]
4. Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers.
Kwon MJ; Kim JW; Jeon JY; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Min KW; Choe JY; Lee HK
Pathol Res Pract; 2017 Apr; 213(4):381-388. PubMed ID: 28214200
[TBL] [Abstract][Full Text] [Related]
5. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
[TBL] [Abstract][Full Text] [Related]
6. KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma.
Fu T; Guzzetta AA; Jeschke J; Vatapalli R; Dave P; Hooker CM; Morgan R; Iacobuzio-Donahue CA; Liu B; Ahuja N
Int J Cancer; 2013 Jun; 132(11):2502-9. PubMed ID: 23065691
[TBL] [Abstract][Full Text] [Related]
7. Survival in ampullary cancer: potential role of different KRAS mutations.
Valsangkar NP; Ingkakul T; Correa-Gallego C; Mino-Kenudson M; Masia R; Lillemoe KD; Fernández-del Castillo C; Warshaw AL; Liss AS; Thayer SP
Surgery; 2015 Feb; 157(2):260-8. PubMed ID: 25616942
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.
Zhuang R; Li S; Li Q; Guo X; Shen F; Sun H; Liu T
PLoS One; 2017; 12(8):e0182562. PubMed ID: 28796802
[TBL] [Abstract][Full Text] [Related]
9. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
10. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
11. K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.
Li T; Zheng Y; Sun H; Zhuang R; Liu J; Liu T; Cai W
Med Oncol; 2016 Jul; 33(7):61. PubMed ID: 27225938
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.
Franko J; Krasinskas AM; Nikiforova MN; Zarnescu NO; Lee KK; Hughes SJ; Bartlett DL; Zeh HJ; Moser AJ
J Gastrointest Surg; 2008 Oct; 12(10):1664-72; discussion 1672-3. PubMed ID: 18677542
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis.
Bunduc S; Gede N; Váncsa S; Lillik V; Kiss S; Dembrovszky F; Eróss B; Szakács Z; Gheorghe C; Mikó A; Hegyi P
Crit Rev Oncol Hematol; 2022 Jan; 169():103548. PubMed ID: 34843928
[TBL] [Abstract][Full Text] [Related]
14. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
15. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis.
Andreatos N; Ronnekleiv-Kelly S; Margonis GA; Sasaki K; Gani F; Amini N; Wilson A; Pawlik TM
Surg Oncol; 2016 Sep; 25(3):332-8. PubMed ID: 27566041
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis.
Tao LY; Zhang LF; Xiu DR; Yuan CH; Ma ZL; Jiang B
World J Surg Oncol; 2016 May; 14():146. PubMed ID: 27183870
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
19. Biological identification of ampullary adenocarcinomas.
Relias V; Saif MW
JOP; 2014 Jul; 15(4):306-7. PubMed ID: 25076327
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
